Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients With Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy

NCT05156320 is registered in ClinicalTrials.gov with Scholar Rock, Inc. as lead sponsor.

NCT NCT05156320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05156320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients With Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy
Lead sponsor
Scholar Rock, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 14, 2022
Completion date
December 18, 2024
Enrollment
188 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

anti-myostatin, atrophy, muscular atrophy, muscular atrophy, spinal, neuromuscular diseases, neuromuscular manifestations, sma, spinal muscular atrophy, spinal muscular atrophy type 2, spinal muscular atrophy type 3